#Life Sciences #AI Innovation #Haier Biomedical

Haier Biomedical's Remarkable 2025 Revenue Growth

Introduction

In the dynamic landscape of life sciences, Haier Biomedical (688139.SH) has established itself as a dominant player. The company recently released its annual report for 2025, showcasing a phenomenal revenue growth of 17.9% year-on-year, culminating in a total revenue of 2.33 billion yuan (approximately $340.77 million USD). Notably, 36% of this revenue came from international markets, marking a significant milestone in the company’s global operations.

Global Expansion Strategy

Over the past decade, Haier Biomedical has transitioned from merely exporting products to effectively globalizing its brand. This strategic shift has yielded impressive results, with double-digit revenue increases across various markets, such as Europe, Asia-Pacific, North America, and Africa. The Asia-Pacific region led the charge with an astonishing growth rate of 26%, while Europe followed closely with a 16% increase.

These results can be attributed to Haier Biomedical's commitment to innovation and expansion into new medical sectors. The company has broadened its operational scope to include smart pharmaceuticals, blood technology, and integrated laboratory solutions, which collectively accounted for a healthy 48.5% of its total revenue.

AI-Driven Innovations

A notable aspect of Haier Biomedical’s growth is its investment in AI technologies. In 2025, AI applications represented 15% of total revenue, showing a solid increase of 2.5 percentage points from the previous year. The company has constructed a multi-layered AI infrastructure incorporating advanced models and AI agents, significantly enhancing productivity in automated pharmaceutical dispensing.

A benchmark achievement was the launch of fully automated cell workstations that won prestigious awards for groundbreaking technology and product innovation. This technology supports critical medical applications, including bio-artificial liver therapies, further establishing Haier Biomedical as an industry leader.

Commitment to Sustainability and Quality

Haier Biomedical’s ultra-low temperature biomedical freezers have set a new standard by capturing the top market shares in countries such as Italy. The company's dedication to sustainable practices is exemplified by its adherence to EU-MDR certification for its plasma separation systems. Furthermore, its